Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8N145
UPID:
LGI3_HUMAN
Alternative names:
LGI1-like protein 4; Leucine-rich glioma-inactivated protein 3
Alternative UPACC:
Q8N145; A5PLP2; Q86TL4; Q8N296
Background:
Leucine-rich repeat LGI family member 3, also known as LGI1-like protein 4 or Leucine-rich glioma-inactivated protein 3, plays a crucial role in the regulation of neuronal exocytosis. This protein, encoded by the gene with the accession number Q8N145, is pivotal in the functioning of the nervous system.
Therapeutic significance:
It is linked to a rare autosomal recessive disorder characterized by developmental delay, intellectual disability, and skeletal defects. Understanding the role of Leucine-rich repeat LGI family member 3 could open doors to potential therapeutic strategies for treating such neurological and developmental disorders.